Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with invasive breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ, confirmed by a tissue biopsy
• Women between the ages of 18 and 75
• People with a general health and activity level that falls within a certain range, as measured by a standard medical scoring system called the ECOG scale (scores 0–2, meaning able to carry out normal daily activities or limited only in physically strenuous activity) (confirm with trial site)
• People whose cancer stage or post-surgery findings mean their treating doctor has recommended radiotherapy after surgery, based on specific staging criteria (confirm with trial site)
• People whose planned radiotherapy follows a specific schedule involving the chest wall or breast area, with set radiation doses delivered over 15 sessions
• People whose recent blood test results (taken within 28 days before joining) meet minimum levels for red blood cells, white blood cells, and platelets, and show the liver and kidneys are functioning within acceptable ranges
• Women who could become pregnant must have had a negative pregnancy blood test within 7 days before the first dose, and must be willing to use a highly effective form of contraception during the trial and for 120 days after the last dose; male participants whose partners could become pregnant must be surgically sterilised or willing to use a highly effective form of contraception during the same period
• People who have voluntarily agreed to take part, signed an informed consent form, and are willing to attend follow-up appointments

Who may not be able to join:

• Men with breast cancer
• People who are not suitable for the specific type of radiotherapy schedule used in this trial (for example, due to lymph node involvement in certain areas, or personal refusal of this radiotherapy approach)
• People who have an active, known, or suspected autoimmune disease that currently requires systemic treatment to suppress the immune system
• People who are currently taking part in another clinical trial, or whose previous clinical trial ended less than 4 weeks ago
• People with a known or strongly suspected history of a lung condition called interstitial pneumonia, or a condition that could interfere with detecting or managing lung-related side effects from the study drug
• People with a history of another type of cancer, unless they completed treatment that could have cured it and have had no recurrence for at least 5 years
• Women who are pregnant, or people with a diagnosed mental illness
• People who have previously received radiotherapy or chemotherapy
• People with active tuberculosis
• People with a severe ongoing lung infection requiring systemic treatment
• People who have had significant coughing up of blood (2.5 mL or more per day) in the two months before joining the trial
• People with serious heart conditions, including severe heart failure, poorly controlled coronary artery disease, certain irregular heart rhythms, or a heart attack in the six months before screening
• People with a known positive HIV diagnosis or a history of AIDS
• People with untreated active hepatitis B or hepatitis C, or both at the same time
• People who, in the investigator's judgement, have other serious medical conditions, significantly abnormal test results, or personal or social circumstances that could affect their safety or the reliability of the trial data

Important: Always verify eligibility with the trial site directly before applying.